

6th Annual
Miami Thyroid Oncology
Symposium

October 27-28, 2023

Virtual Event

Frontiers in Thyroid Oncology
RAI Theranostics

Featured Workshop
Dosimetry and Radiobiology of RAI

Symposium Overview



We welcome you to the 6th Annual Miami Thyroid Oncology Symposium to discuss the rapidly expanding science of “Thyroid Oncology”. The science of thyroid cancer diagnosis and treatment, specifically, the new paradigms of molecular pathology, nuclear theranostics and the new philosophy and techniques of surgery.

A broad catalogue of genomic and epigenomic markers have been identified and integrated in the cytologic and pathologic evaluation of nodular thyroid disease and thyroid cancer. Risk stratification systems that are critical for initial surgical treatment and subsequent use of radioactive iodine treatment rely more on distinct molecular markers, and involving theranostic considerations. The traditional characterization of tumor differentiation/de-differentiation for the purposes of clinical prognostic assessments and more importantly definition/redefinition of the role for RAI treatment for individual cancer phenotypes are now being expressed by molecular characteristics.

The Miami Thyroid Oncology Symposium offers a platform for in depth discussions of the science of thyroid cancer diagnosis and treatment in this new paradigm. It is a unique scientific forum where practicing physicians learn how to adopt and incorporate the new diagnostic and treatment tools and techniques into their daily practice.

The symposium is a two-day program. The first day of the symposium on Friday October 27, 2023 where we will highlight Frontiers in Thyroid Oncology. This session brings together world renowned experts presenting and discussing the state of the art in Thyroid cancer diagnosis and treatment. The second day of the symposium on Saturday, October 28, 2023 will feature a workshop on Advances in Radioactive iodine (RAI) Theranostics, which will provide in depth overview of RAI theranostics and address current controversies on RAI imaging, ablation and approaches for RAI-indifferent cancers.

The 2023 Miami Thyroid Oncology Symposium (MTOS) will be held in a hybrid format. The core faculty will gather at the MTOS conference center and jointly run sessions with participation of international guest faculty and symposium registrants. The sessions will involve brief formal presentations, case discussions, panel debates and Q&A. Technical topics will include video presentations as well.

We are committed to uphold the high-quality symposium standards we have built in the prior years. We are indebted to our world-renowned faculty for taking part in this exciting new scientific platform. We also hope to expand our attendance by reaching to a larger national and international audience via the hybrid format.

Seza Gulec

Seza Gulec, MD, FACS, FACNM
Symposium Director
MCRC President and Chairman of the Board



DRAFT

Symposium Core Faculty

Seza Gulec, MD, FACS, FACNM, Symposium Director

Professor of Surgery and Nuclear Medicine, Florida International University College of Medicine
President of Medical staff, Aventura Hospital and Medical Center, Miami FL
President and Chairman of the Board, Miami Cancer Research Center

Anesa Ahamad, MD

Associate Professor, University of Miami Miller School of Medicine and
Radiation Oncologist, HCA Aventura Hospital

Maria Cabanillas, MD

Professor and Faculty Director of Clinical Research
Department of Endocrine Neoplasia, MD Anderson, Houston, TX


James A. Fagin, MD

Division Head, Subspecialty Medicine, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College, New York, NY

Ashok Shaha, MD

Professor of Surgery, Cornell University Medical College and
Allan H. Selig Chair, Memorial Sloan Kettering Cancer Center, New York City, NY

Yuri Nikiforov, MD



DRAFT

Symposium Invited Faculty

Neeta Pandit-Taskar, MD

Professor of Radiology, Weill Cornell Medical College and Nuclear Medicine Physician & Early Drug Development Specialist, Memorial Sloan Kettering Cancer Center, New York City, NY

Jan Smit, MD

Professor

Manuel Szejnberg, MD

Associate Professor, Universidad Favaloro, Argentina

Serdar Tezelman, MD

Professor, Department of General Surgery, Koç University School of Medicine, Istanbul, Turkey

Robert Flavell, MD

Associate Professor, Department of Radiology, University of California San Francisco School of Medicine

Luca Giovanella, MD

Professor of Nuclear Medicine, Clinic of Nuclear Medicine and Thyroid Centre
Imaging Institute of Southern Switzerland, Bellinzona, Switzerland

Frederick Grant, MD

Department of Radiology, Children's Hospital of Philadelphia, Perelman School of Medicine
University of Pennsylvania, Philadelphia, PA


Atil Kargi, MD

Associate Professor of Clinical Medicine, University of Miami Miller School of Medicine

Jasna Milhailovic, MD

Professor and Head of Department of Nuclear Medicine,
Oncology Institute of Vojvodina, Sremska Kameica, Serbia

Helen Nadel, MD





Frontiers in Thyroid Oncology
Friday, October 27, 2023
8:00a - 6:00p

FRIDAY, OCTOBER 27, 2023 ONCOLOGY TRACK

8:00 - 8:15	Welcome and Acknowledgments	Gulec
8:15 - 8:45	Genomic and Transcriptomic Hallmarks of mis-differentiated and undifferentiated Cancers	Fagin
8:45 - 9:15	Signaling pathways involved in thyroid cancer oncogenesis: Is ERK a central modulator	Cabanillas
9:15 - 9:45	Molecular Theranostics and Thyroid Differentiation Score	McGoron
9:45 - 10:00	Break	
10:00 - 10:30	Prognostic and Theranostic Risk Stratification Systems	Smit
10:30 - 11:00	Diagnostic and Prognostic role of miRNAs in Thyroid Cancer	
11:00 - 12:00	Panel Discussion [Moderators: Cabanillas/McGoron]	
12:00 - 13:00	Lunch [Satellite Symposium]	
13:00-13:30	Intellectual and Scientific Basis of Thyroidectomy	Gulec
13:30 - 14:00	The techniques for thyroidectomy and functional neck dissection	Tezelman
14:00 - 14:30	Surgical challenges and strategies: locally advanced disease	Shaha
14:30 - 14:45	Break	
14:45 - 15:15	Beta knife thyroid remnant ablation: Trials and tribulations	Flavell
15:15 - 15:45	The Diagnostic and Theranostic role of Molecular Cytology	Kargi
15:45 - 17:00	Panel Discussion [Moderators: Shaha/Gulec]	
17:00 - 17:15	Closing Remarks	Gulec
17:15 - 18:00	Satellite Symposium: RFA of thyroid cancer	



Advances in Radioactive Iodine Theranostics
Saturday, October 28, 2023
8:00a - 6:00p

SATURDAY, OCTOBER 28, 2023 NUCLEAR MEDICINE TRACK

8:00 - 8:15	Welcome and Acknowledgments	Gulec
8:15 - 8:45	Intellectual and Scientific Basis of RAI Treatment	Grant
8:45 - 9:15	RAI Indifference and Refractory Thyroid Cancer	
9:15 - 9:45	Novel strategies for systemic treatment of thyroid cancer	Fagin
9:45 - 10:00	Break	
10:00 - 10:30	Diagnostic, theranostic and prognostic value of Thyroglobulin	Giovanella
10:30 - 11:00	Molecular therapeutics in Mis-differentiated and undifferentiated thyroid cancer	Cabanillas
11:00 - 12:00	Panel Discussion [Moderators: Cabanillas/Grant]	
12:00 - 13:00	Lunch [Satellite Symposium]	
13:00-13:30	Surgical challenges and strategies in Recurrent disease	Shaha
13:30 - 14:00	Radiobiology and Dosimetry of RAI in Thyroid Cancer	Gulec
14:00 - 14:30	Evolving radiobiological concepts in EBRT of thyroid cancer	Ahamad
14:30 - 14:45	Break	
14:45 - 15:15	Pre and post-ablation I131RAI imaging	Milhailovic
15:15 - 15:45	I-124 RAI imaging and dosimetry	Pandit
15:45 - 17:00	Panel Discussion [Moderators: Nadel/Pandit]	
17:00 - 17:15	Closing Remarks	Gulec
17:15 - 18:00	Satellite Symposium: Sub-voxel Dosimetry for RAI: Follicular and Cellular microdosimetry	Sztenejnberg

DRAFT

Organizing Committee

Seza Gulec, MD, FACS, FACNM, Symposium Director

Professor of Surgery and Nuclear Medicine, Florida International University College of Medicine
President Elect, Medical staff, Aventura Hospital and Medical Center, Miami FL
President and Chairman of the Board, Miami Cancer Research Center

Anthony McGoron, PhD, Symposium Moderator


Professor of Biomedical Engineering and Associate Dean for Academic Affairs,
Florida International University College of Engineering and Computing
Advisory Board Member, Miami Cancer Research Center, Miami, FL

Paul Perales-Villarreal, MD, Symposium Administrator

Chief Operating Officer
Miami Cancer Research Center, Miami, FL

Dahlia Mohammed, MPH, Symposium Planner

Vice President, Operations
Miami Cancer Research Center, Miami, FL



DRAFT


Symposium Faculty




Seza Gulec, MD, FACS, FACNM, Symposium Director

Professor of Surgery and Nuclear Medicine, Florida International University College of Medicine
President of Medical staff, Aventura Hospital and Medical Center, Miami FL
President and Chairman of the Board, Miami Cancer Research Center

Dr. Seza Gulec is a surgical oncologist/endocrinologist and nuclear oncologist. He is a professor of Surgery, nuclear medicine and biomedical engineering at Florida International University. Dr. Gulec obtained his MD degree at Ankara University Faculty of Medicine in Ankara, Turkey. He trained in surgery at Hacettepe University Faculty of Medicine in Ankara, and at Louisiana State University School of Medicine in New Orleans. He received his nuclear medicine and nuclear oncology training at Memorial Sloan Kettering Cancer Center, and his surgical oncology/endocrinology training at John Wayne Cancer Institute. He currently holds multiple clinical and administrative positions at Florida International University, Aventura Hospital and Medical Center and Miami Cancer Research Center in Miami, FL. Dr. Gulec is a renowned thought leader in thyroid cancer and neuroendocrine tumors. He has successfully combined his clinical and research expertise in the fields of surgical oncology and nuclear medicine. Dr. Gulec is a prolific academic surgeon. He has more than hundred peer-reviewed publications, ten book chapters, and countless presentations at national and international meetings.





Dr. Fagin obtained his medical degree from the University of Buenos Aires in Argentina. After clinical training in Argentina and the United Kingdom, he performed research in pituitary tumorigenesis in the laboratory of Dr. Shlomo Melmed at Cedars-Sinai Medical Center in Los Angeles. He started his own group at that institution before accepting the position of Professor and Chief of Endocrinology at the University of Cincinnati in Ohio from 1995-2006. From 2006-2019 he was Chief of the Endocrinology Service at Memorial Sloan Kettering Cancer Center in New York. He is currently the Head of the Division of Subspecialty Medicine and a Member of the Human Oncology and Pathogenesis Program (HOPP) at MSK, and a Professor of Medicine at the Weill Cornell Medical College of Cornell University. The focus of his work is to understand the pathogenesis and the biology of thyroid cancers with the goal of identifying new mechanism-based therapies. His group has been instrumental in characterizing somatic genetic changes associated with thyroid tumor initiation and progression in radiation-induced and sporadic thyroid cancer, and in defining their functional consequences. He showed that selective MEK and RAF kinase inhibitors restored responsiveness to radioactive iodine in mouse models of the disease and has successfully translated this research to clinical trials.


[illegible]

DRAFT

Symposium Faculty


Atil Kargi, MD

Associate Professor of Medicine and Endocrinology
University of Miami Miller School of Medicine



Dr. Kargi is an associate professor of clinical medicine and J. Maxwell McKenzie Fellowship program director at University of Miami Miller School of Medicine. Dr. Kargi obtained his medical degree in Izmir, Turkey. He completed internal medicine residency at the University of Pittsburgh and fellowship in endocrinology at the University of Washington in Seattle, WA. During his fellowship Dr. Kargi performed basic science research investigating the mechanisms linking inflammation with lipoprotein metabolism and atherosclerosis.

Dr. Kargi is the Director of the Endocrinology Fellowship Program at the University of Miami and directs the Endocrine Testing Center. Dr. Kargi's clinical and research interests include the role of molecular tests and ultrasound in diagnosis of thyroid tumors, the diagnosis of growth hormone deficiency, treatment of male hypogonadism, and tumors of the adrenal and pituitary glands.



DRAFT


Symposium Faculty



Maria Cabanillas, MD



Professor and the Faculty Director of Clinical Research
Department of Endocrine Neoplasia, MD Anderson, Houston, TX

Maria E. Cabanillas, M.D. is an Oncologic Endocrinologist at the University of Texas MD Anderson Cancer Center in Houston, Texas. She is a tenured Professor and the Faculty Director of Clinical Research in the department of Endocrine Neoplasia at MD Anderson. As a clinician and clinical researcher, she treats both early and advanced thyroid cancers, including medullary, differentiated, and anaplastic thyroid cancers. Her research focus is in advanced and aggressive thyroid cancer, with an emphasis that includes molecular targeted therapies and immunotherapy. Dr. Cabanillas led the effort to create FAST, Facilitating Anaplastic thyroid cancer Specialized Treatment at MD Anderson. This multidisciplinary group sees the highest volume of anaplastic thyroid cancer patients in the nation. They have focused their efforts on streamlining the process to see these complex patients, tailor treatment plans based on the molecular abnormalities in the tumor and designing clinical trials for this patient population. Dr. Cabanillas serves as the principal investigator on several clinical trials for the treatment of advanced thyroid cancer. She completed her service recently on the 2021 anaplastic thyroid cancer guidelines committee for the American Thyroid Association that were recently published. She has been a member of the International Thyroid Oncology Group (ITOG) since 2012 and completed her term on the Board of Directors in 2020.



DRAFT

Symposium Faculty



Luca Giovanella, MD


Professor of Nuclear Medicine, Clinic of Nuclear Medicine and Thyroid Centre
Imaging Institute of Southern Switzerland, Bellinzona, Switzerland



Dr. Luca Giovanella completed Medical School of University of Pavia. Subsequently, he obtained his post-graduate Degree in Nuclear Medicine and in Endocrinology at the University of Milan, and the Executive Master in Health Organisation and Human Resources Management at Politecnico Universitario of Milan. He served as a Consultant at the Department of Nuclear Medicine-University Hospital “Fondazione Macchi” of Varese. Since 2003, Dr. Giovanella has served as the Chief of the Department of Nuclear Medicine and PET/CT Centre at Oncology Institute of Southern Switzerland of Bellinzona. Additionally, since 2008 Dr. Giovanella serves as Titular Professor at the Institute of Nuclear Medicine, University of Zürich, Switzerland.

DRAFT

Symposium Faculty



Frederick Grant, MD

Department of Radiology, Children's Hospital of Philadelphia,
Perelman School of Medicine
University of Pennsylvania, Philadelphia, PA

Dr. Grant received his M.D. degree at the State University of New York (SUNY) Upstate Medical University. Dr. Grant completed an Internal Medicine residency at University of Pittsburgh Medical Center. Dr. Grant went on to do a clinical and research fellowship in Endocrinology and Hypertension at the Brigham and Women's Hospital (BWH) and Harvard Medical School. He then trained in the Joint Program in Nuclear Medicine (JPNM) at Harvard Medical School. He also completed a residency in Diagnostic Radiology at the Mount Auburn Hospital, Harvard Medical School, and then a Pediatric Radiology clinical fellowship. Dr. Grant was a staff physician in the Division of Nuclear Medicine and Molecular Imaging at Boston Children's Hospital and was a member of the Dana Farber/Harvard Cancer Center. He also was a member of the Endocrinology divisions at Brigham and Women's Hospital and Boston Children's Hospital. Dr. Grant currently is at the Department of Radiology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania. His clinical and research interests include oncologic and endocrinologic imaging, new PET radiopharmaceuticals, radionuclide therapy, and radiation dose reduction.

Miami Thyroid Oncology Symposium is organized by the Miami Cancer Research Center. Miami Cancer Research Center (MCRC) is a scientific and charitable organization that performs and supports cancer research, organizes educational events and provides support for cancer care at institutional and individual levels. The mission of the MCRC is to take part in the global fight against cancer through research, education and patient care support.



DRAFT

6th ANNUAL Miami Thyroid Oncology Symposium October 27-28, 2023

Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Dade County Medical Association and Miami Cancer Research Center. The Dade County Medical Association is accredited by the Florida Medical Association to provide continuing medical education for physicians. DCMA designates this educational activity for a maximum of 16 AMA PRA Category 1 credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Symposium Support

This symposium is supported by commercial sponsorship by the following industry partners:

Platinum Sponsors



Gold Sponsors

Silver Sponsors

Bronze Sponsors

miamicancerresearch.org



October 27-28, 2023